InMed Pharmaceuticals Inc.

IN on CNSXToday's ChangeVol. / Avg.52 Week Range (Low/Hi)Market Cap
0.39CAN 0.000/0.00%0.08 / 0.56-
IMLFF on OTCQBToday's ChangeVol. / Avg.52 Week Range (Low/Hi)Market Cap
0.29US 0.008/2.81%447,861/812,6200.05 / 0.4315.07M
Powered by: Google Finance

Contact Information

InMed Pharmaceuticals Inc.

Headquarters:
409 Granville Street, #350
Vancouver, British Columbia
V6C 1T2, Canada
Tel: (604) 669-7207
Fax: (604) 683-2506
Email: Send a message
Website: Visit website
For more information...
Lead: Barry Mire

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary bioinformatics drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com

Eric A. Adams - President & CEO

Dr. Sazzad Hossain, Ph.D., M.Sc. - Chief Scientific Officer

Dr. Ado Muhammed, MD, DPM, MFPM - Chief Medical Officer

Alexandra D.J. Mancini, M.Sc. - Senior Vice President, Clinical and Regulatory Affairs.

Chris Bogart - SVP, Corporate Strategy & Investor Relations

Terese Giesleman - Chief Financial Officer

Jeff Charpentier CPA, CA - Chief Financial Officer & Corporate Secretary

Eric A. Adams - President & CEO

Adam Cutler, B.A. - Director

Bill Garner, M.D. - Director

Craig Schneider, B.A. - Director

Andrew Hull, B.Sc. - Director

Martin Bott, MIBS - Director

Stock Information

IN on CNSX
0.00CAN
Today's Change
0.00/0.00%
Volume
0
IMLFF on OTCQB
0.29US
Today's Change
0.01/2.81%
Volume
447,861

Company Overview

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary bioinformatics drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com

Management

Eric A. Adams - President & CEO

Dr. Sazzad Hossain, Ph.D., M.Sc. - Chief Scientific Officer

Dr. Ado Muhammed, MD, DPM, MFPM - Chief Medical Officer

Alexandra D.J. Mancini, M.Sc. - Senior Vice President, Clinical and Regulatory Affairs.

Chris Bogart - SVP, Corporate Strategy & Investor Relations

Terese Giesleman - Chief Financial Officer

Jeff Charpentier CPA, CA - Chief Financial Officer & Corporate Secretary

Board of Directors

Eric A. Adams - President & CEO

Adam Cutler, B.A. - Director

Bill Garner, M.D. - Director

Craig Schneider, B.A. - Director

Andrew Hull, B.Sc. - Director

Martin Bott, MIBS - Director

Contact Information

Headquarters:
409 Granville Street, #350
Vancouver, British Columbia
V6C 1T2, Canada
Telephone: (604) 669-7207
Fax: (604) 683-2506
Email: Send a message
Website: Visit website